Comprehensive Cancer Panel Sequencing Defines Genetic Diversity and Changes in the Mutational Characteristics of Pancreatic Cancer Patients Receiving Neoadjuvant Treatment
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Pancreatic ductal adenocarcinoma (PDA) is associated with an extremely poor prognosis. This study assessed the genetic diversity among patients with PDA and compared their mutational profiles before and after treatment. Methods: Tumors and matched blood samples were obtained from 22 PDA patients treated with neoadjuvant chemoradiation therapy. The somatic mutations were analyzed with comprehensive cancer gene panel (CCP). In addition, the biopsy samples obtained at diagnosis and the surgically resected samples after treatment were compared for seven patients. The CCP provided formalin-fixed paraffin-embedded sample-compatible multiplexed target selection for 409 genes implicated in cancer. Results: Assessments of the MLH1, MLH3, MSH2, and PMS2 genes showed that the four patients with the highest relative burdens of mutations harbored somatic mutations in at least three of these genes. Genes in the histone-lysine N-methyltransferase 2 (KMT2) family, such as KMT2D, KMT2A, and KMT2C, were frequently mutated in tumor samples. Survival was worse in patients with ARID1A gene mutations than those without ARID1A gene mutations. Mutation patterns were compared between tissue samples before and after neoadjuvant treatment in seven patients who underwent surgical resection. The allelic fraction of mutations in KRAS codon 12 was lower in the surgically resected samples than in the endoscopic ultrasonography-guided fine needle aspiration biopsy samples of six patients. The number of mutant alleles of the histone lysine methyltransferase gene WHSC1 also decreased after treatment. Conclusions: These results indicate that tumor tissue from PDA patients is genetically diverse and suggest that ARID1A mutations may be a potential prognostic marker for PDA.
Abstract
Background/Aims: Pancreatic ductal adenocarcinoma (PDA) is associated with an extremely poor prognosis. This study assessed the genetic diversity among patients with PDA and compared their mutational profiles before and after treatment. Methods: Tumors and matched blood samples were obtained from 22 PDA patients treated with neoadjuvant chemoradiation therapy. The somatic mutations were analyzed with comprehensive cancer gene panel (CCP). In addition, the biopsy samples obtained at diagnosis and the surgically resected samples after treatment were compared for seven patients. The CCP provided formalin-fixed paraffin-embedded sample-compatible multiplexed target selection for 409 genes implicated in cancer. Results: Assessments of the MLH1, MLH3, MSH2, and PMS2 genes showed that the four patients with the highest relative burdens of mutations harbored somatic mutations in at least three of these genes. Genes in the histone-lysine N-methyltransferase 2 (KMT2) family, such as KMT2D, KMT2A, and KMT2C, were frequently mutated in tumor samples. Survival was worse in patients with ARID1A gene mutations than those without ARID1A gene mutations. Mutation patterns were compared between tissue samples before and after neoadjuvant treatment in seven patients who underwent surgical resection. The allelic fraction of mutations in KRAS codon 12 was lower in the surgically resected samples than in the endoscopic ultrasonography-guided fine needle aspiration biopsy samples of six patients. The number of mutant alleles of the histone lysine methyltransferase gene WHSC1 also decreased after treatment. Conclusions: These results indicate that tumor tissue from PDA patients is genetically diverse and suggest that ARID1A mutations may be a potential prognostic marker for PDA.
참고문헌 (30)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014", Cancer Research and Treatment, 49(2), pp.292~305 (2017), 대한암학회
- 오창모, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2013", Cancer Research and Treatment, 48(2), pp.436~450 (2016), 대한암학회
- Ryan DP, "Pancreatic adenocarcinoma", N Engl J Med, 371, pp.1039~1049 (2014)
- Von Hoff DD, "Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine", N Engl J Med, 369, pp.1691~1703 (2013)
- Garrido-Laguna I, "Pancreatic cancer : from state-of-the-art treatments to promising novel therapies", Nat Rev Clin Oncol, 12, pp.319~334 (2015)
- Bournet B, "Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer : hopes and realities", Eur J Cancer, 54, pp.75~83 (2016)
- Kwon MJ, "Low frequency of KRAS mutation in pancreatic ductal adenocarcinomas in Korean patients and its prognostic value", Pancreas, 44, pp.484~492 (2015)
- Biankin AV, "Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes", Nature, 491, pp.399~405 (2012)
- Cowley MJ, "Understanding pancreatic cancer genomes", J Hepatobiliary Pancreat Sci, 20, pp.549~556 (2013)
- Waddell N, "Whole genomes redefine the mutational landscape of pancreatic cancer", Nature, 518, pp.495~501 (2015)
- Wood LD, "Pancreatic cancer genomes : toward molecular subtyping and novel approaches to diagnosis and therapy", Mol Diagn Ther, 17, pp.287~297 (2013)
- Buys SS, "A study of over 35, 000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes", Cancer, 123, pp.1721~1730 (2017)
- Malapelle U, "Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients", Br J Cancer, 116, pp.802~810 (2017)
- Rathi V, "Clinical validation of the 50 gene AmpliSeq Cancer Panel V2 for use on a next generation sequencing platform using formalin fixed, paraffin embedded and fine needle aspiration tumour specimens", Pathology, 49, pp.75~82 (2017)
- 우상명, "Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost–Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study", Cancer Research and Treatment, 49(4), pp.1022~1032 (2017), 대한암학회
- Do H, "Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil-DNA glycosylase", Oncotarget, 3, pp.546~558 (2012)
- Serizawa M, "The efficacy of uracil DNA glycosylase pretreatment in amplicon-based massively parallel sequencing with DNA extracted from archived formalin-fixed paraffin-embedded esophageal cancer tissues", Cancer Genet, 208, pp.415~427 (2015)
- McKenna A, "The Genome Analysis Toolkit : a MapReduce framework for analyzing next-generation DNA sequencing data", Genome Res, 20, pp.1297~1303 (2010)
- Li H, "Fast and accurate short read alignment with Burrows-Wheeler transform", Bioinformatics, 25, pp.1754~1760 (2009)
- Li H, "Fast and accurate long-read alignment with Burrows-Wheeler transform", Bioinformatics, 26, pp.589~595 (2010)
- Cibulskis K, "Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples", Nat Biotechnol, 31, pp.213~219 (2013)
- Saunders CT, "Strelka : accurate somatic small-variant calling from sequenced tumor-normal sample pairs", Bioinformatics, 28, pp.1811~1817 (2012)
- Sim NL, "SIFT web server: predicting effects of amino acid substitutions on proteins", Nucleic Acids Res, 40, pp.W452~W457 (2012)
- Adzhubei I, "Predicting functional effect of human missense mutations using PolyPhen-2", Curr Protoc Hum Genet, 76, pp.7.20.1~7.20.41 (2013)
- Cerami E, "The cBio cancer genomics portal : an open platform for exploring multidimensional cancer genomics data", Cancer Discov, 2, pp.401~404 (2012)
- Gao J, "Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal", Sci Signal, 6, pp.pl1~ (2013)
- Turner NC, "Genetic heterogeneity and cancer drug resistance", Lancet Oncol, 13, pp.e178~e185 (2012)
- Wang Z, "Pancreatic cancer : understanding and overcoming chemoresistance", Nat Rev Gastroenterol Hepatol, 8, pp.27~33 (2011)
- Witkiewicz AK, "Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets", Nat Commun, 6, pp.6744~ (2015)
- Sausen M, "Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients", Nat Commun, 6, pp.7686~ (2015)